Zevra Therapeutics (ZVRA) Q4 2025 Earnings
How Did ZVRA Stock React to Q4 2025 Earnings?
S&P 500 over the same 30 days: +0.34%.
Did ZVRA Beat Earnings? Q4 2025 Results
Yes. Zevra Therapeutics reported Q4 2025 earnings of $0.19 a share on Mar 9, 2026, beating the $0.05 consensus estimate by 322.2%. Revenue was $34.1M against a $28.1M estimate.
Zevra Therapeutics delivered a standout Q4 2025, posting revenue of $34.10 million against a consensus estimate of $28.03 million, a beat of 21.65%, while reporting earnings per share of $0.19 as the company continued its rapid commercial ascent. The single biggest driver was the accelerating uptake of MIPLYFFA for Niemann-Pick disease type C, which generated $26.40 million in Q4 net revenue alone and propelled full-year revenue to a 183.2% year-over-year gain, reflecting the first full year of U.S. commercialization following FDA approval in September 2024. With 161 total patient enrollments since launch and market access now covering 68% of U.S. covered lives, the commercial foundation is broadening steadily. Analysts have broadly maintained a "Moderate Buy" consensus on the stock, and with $238.90 million in cash on hand, the company sees no immediate need to tap capital markets. Looking ahead, Zevra is focused on advancing its EMA review for MIPLYFFA in Europe and engaging the FDA on accelerated development pathways for celiprolol in Vascular Ehlers-Danlos Syndrome.
- Strong MIPLYFFA commercial uptake with 24 Q4 prescription enrollment forms and 161 cumulative since launch
- Market access reached 68% of covered lives for MIPLYFFA
- Gain on sale of Priority Review Voucher of $148.3 million
- R&D expenses decreased $29.4 million year-over-year due to lower personnel and third-party costs
- 113 patients enrolled in global Expanded Access Program
“MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confidence in its long-term potential. We have officially relocated our global corporate headquarters to Boston, enhancing our access to a deep and highly specialized talent pool. Looking ahead, we are focused on executing against multiple near-term growth opportunities in 2026, and believe we are well-positioned to execute on our strategic priorities to create meaningful value for the rare disease community and our shareholders.”
Zevra Therapeutics CEO, on the earnings call
What Was Zevra Therapeutics's Outlook in Q4 2025?
Zevra stated it is focused on executing against multiple near-term growth opportunities in 2026, including broadening access to MIPLYFFA through geographic expansion (EMA review progressing), advancing the Phase 3 DiSCOVER trial for celiprolol in VEDS with FDA engagement on accelerated development, and leveraging its Boston headquarters relocation for talent acquisition. The company believes it has sufficient resources and financial flexibility to execute on its strategic priorities independent from the capital markets, with $238.9 million in cash, cash equivalents and securities.
ZVRA YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $34.1M | $12.0M | +183.2% |
| Net Income | $12.2M | $5.2M | +134.1% |
ZVRA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.